Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals

Ehrlich, GD; Glaser, Jordan B.; Abbott, MA; Slamon, DJ; Keith, Duane E.; Sliwkowski, Mark X.; Brandis, John W.; Keitelman, E; Teramoto, Y A; Papsidero, Lawrence D.

doi:10.1182/blood.v74.3.1066.1066

Cited by 59 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HTLV-1/11 taxhex (regulatory genes) and pol (polymerasekregion primers (Ranki A: unpublished results). The taxlrex region was chosen as the target to be amplified since most HTLV-1-infected individuals form antibodies against only the viral regulatory protein Tax (38).…”

Section: Sle Patients By Pcr-based Amplification Withmentioning

confidence: 99%

Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies

Ranki

Kurki

Riepponen

et al. 1992

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. To study the relationship between antibodies that recognize human retroviral proteins and the presence of clinical features and ribonucleoprotein antibodies in patients with autoimmune connective tissue diseases (CTDs).Methods. Antibodies against native human immunodeficiency virus type 1 (HIV-1) and human T cell leukemiahymphoma virus type I, recombinant HIV-1 Nef protein, and ribonucleoprotein antigens were determined by immunoblot of sera from 65 prospectively studied patients with definite ur suspected CTDs of autoimmune type.Results. Antibodies to retroviral proteins (ARP), most frequently to HIV Gag proteins p55 and p24, were found in 64% of 22 patients with systemic lupus erythematosus (SLE), in 63% of 8 patients with discoid LE From the

show abstract

Section: Sle Patients By Pcr-based Amplification Withmentioning

confidence: 99%

Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies

Ranki

Kurki

Riepponen

et al. 1992

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…The presence of seronegative HTLV-I carriers has been described (Saito et al, 1989;Kajiyama et al, 1990). Some HTLV-I carriers were negative for serum anti-HTLV-I antibodies against viral structural proteins (Ehrlich et al, 1989). A seronegative carrier state has been described in rabbits infected with HTLV-I (Seto et al, 1988).…”

Section: Discussionmentioning

confidence: 99%

“…Several investigators have described the presence of seronegative HTLV-I carriers (Saito et al, 1989;Kajiyama et al, 1990). Some HTLV-I carriers have been reported to be negative for serum anti-HTLV-I antibodies against viral structural proteins on screening examinations (Ehrlich et al, 1989). HTLV-I infection is usually diagnosed by examining serum antibodies against the viral antigens.…”

mentioning

confidence: 99%

Absence of HTLV‐I infection among seronegative subjects in an endemic area of Japan

Kinoshita¹,

Imamura²,

Nagai³

et al. 1993

Intl Journal of Cancer

View full text Add to dashboard Cite

To examine the prevalence of infection by human T-cell leukemia virus type I (HTLV-I) among seronegative subjects, healthy subjects on Tsushima Island, Japan, where the infection is endemic, were evaluated. A total of 209 healthy adults were examined for HTLV-I provirus in peripheral blood mononuclear cells by the polymerase chain reaction (PCR), as well as for anti-HTLV-I antibodies by the particle agglutination (PA) method, the enzyme-linked immunosorbent assay (ELISA) and by immunofluorescence analysis (IF). A total of 76 subjects were positive and 133 were negative for the provirus, showing a close correlation with the results of 3 assays for anti-HTLV-I serum antibodies. None of the seronegative subjects reacted positively on PCR analysis. These observations indicate that seronegative HTLV-I carriers are rare in an area of Japan in which this viral infection is endemic.

show abstract

“…All plasma samples, save for the hypogammaglobulinemia patients, were screened for anti-HIV or anti-HTLV antibodies in FDA-approved whole virus ELISAs. All positives were reanalyzed in duplicate and those scoring positive in at least one replicate were deemed to be repeatedly reactive [14]. All repeatedly reactive HTLV ELISA samples were then confirmed in a radioimmunoprecipitation assay using a 35 S-labeled methionine and cysteine HTLV-I cell lysate, as previously described [14], and in the commercially available DBL 2.3 Western blot assay which, in addition to whole HTLV-I viral proteins, contains recombinant HTLV-I gp21 env protein, recombinant HTLV-I-specific gp46 env peptide, and recombinant HTLV-II-specific gp46 env peptide [15].…”

Section: Serologymentioning

confidence: 99%

Prevalence of HTLV‐I‐associated T‐cell lymphoma

Poiesz

Papsidero²,

Ehrlich

et al. 2001

Am. J. Hematol.

View full text Add to dashboard Cite

In order to assess the prevalence rate of HTLV-I-associated T-cell lymphomas and human retrovirus infection in general, approximately 21,000 individuals representing various patient populations, retroviral risk groups, and blood donors were examined for HTLV-I, HTLV-II, HIV-1, or HIV-2 infection using serologic and PCR assays. The prevalence rates among volunteer blood donors were 0.02% and 0% for HTLV and HIV, respectively. Significantly increased HTLV prevalence rates were observed among paid blood donors, African American health care clinic patients, Amerindians, recipients of HTLV-positive cellular blood products, intravenous drug users, sexual contacts and family members of HTLV-positive people, and patients with primary thrombocytosis and other-than-lowgrade non-Hodgkin's lymphoma (NHL). Among some of these groups there were significant differences in the prevalence of HTLV-I versus HTLV-II. The eight HTLV-positive NHL patients all had mature, high-grade, CD4 + T-cell lymphomas with clonally integrated HTLV-I, for a prevalence of 4% among other-than-low-grade NHL patients. Seven of the eight died from their disease within 2 years despite treatment. Interestingly, two groups at risk for HTLV infection, namely needle stick victims and recipients of HTLV-infected and/or pooled plasma products, showed no evidence for infection. Significantly increased HIV-1 prevalence was observed among paid blood donors, African Americans, homosexuals, female prostitutes, hemophiliacs, and other-than-low-grade NHL patients. Only one patient was infected with HIV-2. Of the nine HIV-positive, other-than-low-grade NHL patients, seven HIV-1 positives had B-cell lymphomas, one HIV-1 positive had an HTLV-I-positive CD4 + T-cell lymphoma, and one infected with HIV-2 had a CD4 + T-cell lymphoma that was HTLV negative. The data indicate that HTLV-I lymphoma, while uncommon, is not necessarily rare among other-than-low-grade NHL cases in the UnitedStates and, given its poor prognosis, should probably be studied separately in clinical trials. Am. J. Hematol. 66:32-38, 2001.

show abstract

Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals

Cited by 59 publications

References 25 publications

Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies

Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies

Absence of HTLV‐I infection among seronegative subjects in an endemic area of Japan

Prevalence of HTLV‐I‐associated T‐cell lymphoma

Contact Info

Product

Resources

About